SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

RECALL CRYPTO is experiencing a surge in interest, with community members actively discussing its recent initial coin offering and potential for high volume gains. Conversations highlight both excitement and caution, with some users pointing to potential rug pull risks, while others express optimism. The coin is also being mentioned alongside other trending tokens like $HONK and $PUMP within the Solana ecosystem.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other Hong Kong-based stocks. Community members are highlighting the company's regained NASDAQ compliance and a substantial contract that exceeds its market capitalization as potential catalysts. High cost to borrow is also fueling speculation.

Towns

Towns Crypto ($TOWNS) is trending as the community discusses its potential for a breakout, comparing it to other tokens like $RECALL and $AVNT. Traders are actively speculating on realistic price targets and debating whether to hold or sell, while also highlighting its Onchain Matrix structure.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype is trending due to ongoing discussions around its potential, recent price movements, and comparisons to other decentralized exchanges. Community members are actively debating its future value and whether it can sustain its current trajectory. Some traders are also noting its technical setups for both long and short positions.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

Jerry The Turtle ($JYAI) is trending as community members anticipate listings on major exchanges like Kraken and KuCoin, with some claiming fees have already been paid. Bullish sentiment is fueled by comparisons to other successful meme coins like Pepe, Shiba Inu, and Dogwifhat, as well as a billboard advertisement and potential partnerships. The community emphasizes holding ('HODL') and buying dips, while highlighting its strong foundation and potential for significant growth.

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Solana Co. - Ordinary Shares - Class A

Solana Co

$HSDT is trending due to a planned $500M Solana-backed treasury, with the community actively discussing its potential as a public market $SOL play.  Traders are weighing whether this move signals a game-changer or a potential dilution trap, while also monitoring the stock's volatility and short squeeze possibilities.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

SYRE (Spyre Therapeutics) is trending due to positive analyst coverage and promising clinical trial updates, driving investor optimism. Community discussions revolve around the company's potential leadership in inflammatory bowel disease (IBD) treatment and the value of its pipeline, particularly extended half-life antibodies. Recent Phase 1 results and upcoming Phase 2 readouts are key catalysts, placing SYRE in an active pharmaceutical M&A area.

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Nextcure Inc

NXTC is trending due to significant after-hours movement, fueled by new preclinical data related to brittle bone disease. The community is discussing the low float, potential for a squeeze, and upcoming catalysts, while some express concerns about management and past performance. This activity places NXTC within the volatile biotechnology sector, known for its potential for both high gains and significant losses.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community debates its potential amid market volatility and compares it to other altcoins. Discussions revolve around its long-term prospects, potential partnerships (such as with Google), and criticisms of its leadership, with some community members calling for changes. Sentiment is mixed, with some viewing dips as buying opportunities and others expressing concern over its performance relative to Bitcoin.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap (UNI) is trending as community members discuss its potential, with some highlighting its annualized fees and others noting recent pullbacks as buying opportunities. There is excitement around potential breakouts, as well as discussion around the broader DeFi space and Uniswap's role within it. Some users are watching key price levels for potential moves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results...

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogens Unsolicited Acquisition Proposal

Sage Therapeutics, Inc. (Nasdaq: SAGE) (Sage or the Company), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sage Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SAGE News

SAGESage Therapeutics Inc